OBJECTIVES: To assess the safety, erectogenic properties, and effect on sexual desire of Melanotan II, a synthetic melanotropic initiator of erection, in men with erectile dysfunction and organic risk factors. METHODS: Ten subjects were enrolled in a double-blind, placebo-controlled, crossover study. Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection; real-time RigiScan monitoring and a visual analog were used to quantify the erections during a 6-hour period. The level of sexual desire and side effects were recorded with a questionnaire. RESULTS:Melanotan II initiated subjectively reported erections in 12 of 19 injections versus only 1 of 21 doses of placebo. The mean rigidity score of the responders was 6.9 on a scale of 0 to 10. The mean duration of tip rigidity greater than 80% was 45.3 minutes with Melanotan II versus 1.9 for placebo (P = 0.047). The level of sexual desire after injection was significantly higher after Melanotan II administration than after placebo. Nausea and stretching/yawning occurred more frequently with Melanotan II, and 4 of 19 injections were associated with severe nausea. CONCLUSIONS: The erectogenic properties of Melanotan II are not limited to cases of psychogenic erectile dysfunction; men with a variety of organic risk factors developed penile erections. The finding of increased sexual desire warrants further investigation of centrally acting agents on disorders of sexual desire.
RCT Entities:
OBJECTIVES: To assess the safety, erectogenic properties, and effect on sexual desire of Melanotan II, a synthetic melanotropic initiator of erection, in men with erectile dysfunction and organic risk factors. METHODS: Ten subjects were enrolled in a double-blind, placebo-controlled, crossover study. Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection; real-time RigiScan monitoring and a visual analog were used to quantify the erections during a 6-hour period. The level of sexual desire and side effects were recorded with a questionnaire. RESULTS: Melanotan II initiated subjectively reported erections in 12 of 19 injections versus only 1 of 21 doses of placebo. The mean rigidity score of the responders was 6.9 on a scale of 0 to 10. The mean duration of tip rigidity greater than 80% was 45.3 minutes with Melanotan II versus 1.9 for placebo (P = 0.047). The level of sexual desire after injection was significantly higher after Melanotan II administration than after placebo. Nausea and stretching/yawning occurred more frequently with Melanotan II, and 4 of 19 injections were associated with severe nausea. CONCLUSIONS: The erectogenic properties of Melanotan II are not limited to cases of psychogenic erectile dysfunction; men with a variety of organic risk factors developed penile erections. The finding of increased sexual desire warrants further investigation of centrally acting agents on disorders of sexual desire.
Authors: Alexander V Mayorov; So-Yeop Han; Minying Cai; Matthew R Hammer; Dev Trivedi; Victor J Hruby Journal: Chem Biol Drug Des Date: 2006-05 Impact factor: 2.817
Authors: Alexander V Mayorov; Minying Cai; Kevin B Chandler; Ravil R Petrov; April R Van Scoy; Zerui Yu; Dustin K Tanaka; Dev Trivedi; Victor J Hruby Journal: J Med Chem Date: 2006-03-23 Impact factor: 7.446
Authors: Lex H T Van der Ploeg; William J Martin; Andrew D Howard; Ravi P Nargund; Christopher P Austin; Xiaoming Guan; Jennifer Drisko; Doreen Cashen; Iyassu Sebhat; Arthur A Patchett; David J Figueroa; Anthony G DiLella; Brett M Connolly; David H Weinberg; Carina P Tan; Oksana C Palyha; Sheng-Shung Pong; Tanya MacNeil; Charles Rosenblum; Aurawan Vongs; Rui Tang; Hong Yu; Andreas W Sailer; Tung Ming Fong; Cathy Huang; Michael R Tota; Ray S Chang; Ralph Stearns; Constantin Tamvakopoulos; George Christ; Deborah L Drazen; Brian D Spar; Randy J Nelson; D Euan MacIntyre Journal: Proc Natl Acad Sci U S A Date: 2002-08-09 Impact factor: 11.205